Strata Critical Medical (SRTA) Cost of Revenue (2021 - 2026)

Strata Critical Medical has disclosed Cost of Revenue across 6 years of filings, most recently posting $53.3 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 84.35% year-over-year to $53.3 million; the TTM figure through Mar 2026 stood at $247.5 million (up 9.88% YoY), while the FY2025 annual figure was $156.0 million, up 33.09% from the prior year.
• Cost of Revenue slipped to $53.3 million in Q1 2026, from $154.9 million in the prior quarter.
• Over the last five years, Cost of Revenue for SRTA reached as high as $175.0 million in Q4 2023 and fell as low as $1.6 million in Q2 2025.
• The 5-year median for Cost of Revenue is $38.1 million (2023), against an average of $55.1 million.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 2017.06% — and 2025, when it plunged 96.83%.
• A 5-year view of Cost of Revenue shows it stood at $30.5 million in 2022, then jumped by 473.47% to $175.0 million in 2023, then slumped by 33.61% to $116.2 million in 2024, then jumped by 33.32% to $154.9 million in 2025, then slumped by 65.62% to $53.3 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $53.3 million, $154.9 million, and $37.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.